The tumor microenvironment (TME) plays an important role in cancer and plays a role in 22 resistance to therapy. In Waldenström macroglobulinemia (WM), a B-cell malignancy 23 characterized by the overproduction of a monoclonal IgM protein, the TME plays an 24 important role in WM biology by secreting cytokines that promote malignant phenotype.
Abstract

21
The tumor microenvironment (TME) plays an important role in cancer and plays a role in 22 resistance to therapy. In Waldenström macroglobulinemia (WM), a B-cell malignancy 23 characterized by the overproduction of a monoclonal IgM protein, the TME plays an 24 important role in WM biology by secreting cytokines that promote malignant phenotype.
25
In previous work, we have shown that TME-IL-6 promotes WM cell growth and IgM 26 secretion in WM. Tocilizumab/Actemra is an anti-IL-6R antibody, which can competitively 27 block IL-6 binding to the IL-6R. We investigated the efficacy of Tocilizumab in a 28 preclinical mouse model of WM that considers the role of the TME in disease biology.
29
Hairless SCID mice were subcutaneously implanted with BCWM.1 or RPCI-WM1 and 30 bone marrow stromal cells. Groups of mice were treated with Tocilizumab or control 31 antibody three times/week for 5 weeks and the effect on tumor burden and disease 32 biology were evaluated. Although Tocilizumab had no effect on mice survival, there was 33 a reduction in tumor growth rate in mice injected with RPCI-WM1 cells treated with 34 Tocilizumab (p=0.0394). In mice injected with BCWM.1 + stromal cells, there was a 35 significant reduction in human IgM secretion in mice sera with Tocilizumab treatment 36 (p=0.0099). There was no significant change in mice weight suggesting Tocilizumab 37 induced no toxicities to the mice. Taken together, our data suggests that administration 38 of Tocilizumab to tumor bearing mice, results in a significant reduction in tumor volume 39 and IgM secretion. Therefore, the evaluation of the role of Tocilizumab in WM patients 40 may provide therapeutic efficacy by reducing IgM production and slowing the rate of 41 tumor growth.
Introduction
47
Waldenström macroglobulinemia (WM) is a subtype of non-Hodgkin lymphoma 48 (NHL) 
66
Despite the progress made to understand disease biology, like most other 67 neoplasms, WM remains an incurable disease and ultimately patients succumb to 68 disease progression. The TME plays an important role in the development and 69 progression of WM and has been shown to play a protective role in resistance to 70 therapy [5] [6] [7] . In fact, the cross-talk between malignant cells and cells in the TME favors 71 disease progression and promotes IgM secretion. In previous studies, we and others 72 4 have shown that IL-6 from the TME promotes IgM secretion and cell growth via binding 73 to the IL-6R on WM cells [8] [9] [10] [11] . Therefore, targeting IL-6/IL-6R signaling may provide 74 therapeutic benefit for WM patients, particularly those with high levels of IgM in their 75 serum.
76
Tocilizumab/Actemra is an anti-IL-6R antibody, which can competitively block IL- 
88
In this study, we report the efficacy of targeting the TME with Tocilizumab in a 89 preclinical mouse model of WM that considers the role of the TME in disease biology.
90
We show that Tocilizumab reduced tumor growth and IgM secretion and suggest it may 91 provide therapeutic benefit to WM patients. 92 93 94
Results
95
Targeting IL-6 in the WM TME does not affect survival
96
Because bone marrow stromal cells in the WM TME are an important source of 97 IL-6, we subcutaneously implanted hairless SCID mice with BCWM.1 cells or RPCI-98 5 WM1 cells and HS-5 stromal cells at a ratio of 5:1 onto the right flank of mice. This 99 allowed us to examine the role of paracrine IL-6 from bone marrow stromal cells, which 100 have been shown to play an important role in malignant B cells in WM [5, 8, 9, 16, 17] , on 101 WM cells in vivo. Upon tumor appearance, we treated mice with either Tocilizumab or 102 IgG control antibody every other day for 5 weeks (Figure 1A) and examined the effect of 103 therapy on mice survival. In accordance with Institutional IACUC, mice were euthanized 104 when tumors reached 2 cm in any dimension or when tumors became ulcerated. We 105 found that Tocilizumab treatment did not affect overall survival in mice xenografted with 106 BCWM.1 or RPCI-WM1 and stromal cells ( Figure 1B) .
108
Targeting IL-6 with Tocilizumab reduces tumor growth and IgM secretion 109 Tumor growth was monitored and recorded 3 times/week. When we examined 110 the rate of tumor growth (tumor growth relative to the size of the first recorded tumor), 111 we found a significant reduction in tumor growth rate in mice implanted with RPCI-WM1 112 and stromal cells, and treated with Tocilizumab (p=0.0394) (Figure 2A) . Although the 113 overall tumor growth rate was not statistically significant in mice implanted with BCWM.1 114 cells and stromal cells, the rate of tumor growth was slower in Tocilizumab treated mice 115 (Figure 2A) . Interestingly, when we examined actual tumor volume and tumor growth 116 rate in mice implanted with BCWM.1 and stromal cells at day 14 (when all mice were 117 alive), we found a significant reduction in tumor growth rate (p=0.0306) ( Figure 2B ). We 118 also found a reduction in the actual tumor volume in this group at day 14, although this 119 did not reach statistical significance (p=0.057) ( Figure 2B) . This is consistent with our 120 previous reports on the effect of IL-6 on malignant cell growth in WM, where IL-6 121 induced a modest increase in WM cell proliferation in this indolent lymphoma [8, 9] .
122
The role of IL-6 in normal and malignant B cell biology is well established [9, 11, 123 18-21] . IL-6 has been shown to promote immunoglobulin (Ig) secretion in normal B cells 124 6 [21] and malignant B cells [9] [10] [11] [18] [19] [20] . We have previously shown that IL-6 promotes 125 IgM secretion in WM [8, 9] . Therefore, we examined the effect of IL-6 therapy on human 126 IgM secretion in mice sera. Consistent with our previous reports, we found a significant 127 reduction in human IgM secretion in mice sera in groups of mice xenografted with 128 BCWM.1 cells and stromal cells, treated with Tocilizumab (p=0.0029) (Figure 3) .
129
However, in mice xenografted with RPCI-WM1 cells and stromal cells, there was no 130 reduction in IgM secretion with Tocilizumab treatment (Figure 3) . The RPCI-WM1 tumors To examine potential therapy-induced toxicities, we monitored the weights of 138 mice three times/week. Tocilizumab treated mice did not differ from control mice in 139 weight in RPCI-WM1 xenografted mice (Figure 4A) . In BCWM.1 xenografted mice, there 140 was a significant (p=0.005) difference in mice weights between Tocilizumab treated mice 141 and control mice (Figure 4A) . However, when we examined individual mice within each 142 group, the data indicates that control mice consistently increased their weight, while the 143 majority (7/10 mice) of Tocilizumab-treated mice either maintained their weight or 144 increased it (Figure 4B) . Taken together, these results suggest that targeting IL-6 in the 145 TME reduced tumor growth rate and IgM secretion while having no toxic effects on mice.
146
We performed immunohistochemical staining of tumor biopsies with H&E and 147 found a similar cellular morphology composed of small round cells in the 2 mice 148 treatment groups (Figure 5) . This is consistent with B cell morphology and suggests 149 growth of WM cells to form these tumors. 7 151 152
Discussion
153
The role of the bone marrow TME in WM and other B cell malignancies is well 154 documented [6, 16, [22] [23] [24] . Interactions between malignant B cells and stromal cells in 155 the TME play an essential role in regulating malignant B cell biology including cell 156 growth, cell survival and Ig secretion [5, 8, 24] . In previous work, we have shown that IL-6 157 levels are elevated in WM patients and IL-6 from human bone marrow stromal cells can 158 promote WM cells growth and IgM secretion [8, 16] . This finding led us to investigate the 159 efficacy of blocking IL-6 to block the interaction between the TME and WM cells. Our 160 results show that targeting IL-6 in the WM TME did not affect the survival in two WM cell 161 line models investigated (Figure 1B) . This finding is not surprising, as IL-6 does not 162 induce apoptosis of WM cells [9] . Rather, the role of IL-6 in WM was shown to promote 163 IgM secretion and WM cell growth [8, 9] . Consistent with this role, we did find a reduction 164 in tumor growth rate when tumor bearing mice were treated with Tocilizumab (Figure 2) .
165
These results indicate that targeting IL-6 in the TME in WM may slow the rate of tumor 166 growth. Since WM remains an incurable disease, a reduction in IgM levels may provide 167 a much needed symptomatic relief for patients. Future studies combining targeting of IL-168 6 with therapies that induce apoptosis of WM cells, may prove to be effective; with IL-6 169 therapy slowing tumor growth and another therapy targeting the malignant cells. 
177
Our results show that tumor-bearing mice treated Tocilizumab had reduced levels of 178 human IgM secretion in mice serum (Figure 3) . Interestingly, RPCI-WM1 tumor-bearing 179 mice treated with Tocilizumab had similar levels of IgM as control mice. The 2 WM cell 180 lines used in this study are derived from different WM patients [26, 27] . Interestingly, 181 RPCI-WM1 cells secrete the highest levels of IgM among the available WM cell lines 182 (data not shown), raising the possibility that the rate of increase in IgM levels in patient 183 may correlate with the efficacy of Tocilizumab monotherapy. Therefore, an examination 184 of the efficacy of IL-6 therapy in WM patients is necessary to evaluate its effect on IgM 185 levels and tumor growth.
186
Taken together, these data suggest that administration of Tocilizumab monotherapy 187 to tumor bearing mice results in a reduction in tumor burden and IgM secretion, despite 188 the presence of IL-6 from bone marrow stromal cells in the TME. Therefore, 189 administration of an anti-IL-6 therapy such as Tocilizumab to WM patients may provide 190 therapeutic efficacy by targeting the TME to reduce IgM production and slow [6, 16, 22- 
